<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D6142A77-0EAB-46B6-BA55-A4B63D1CE79C"><gtr:id>D6142A77-0EAB-46B6-BA55-A4B63D1CE79C</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D029004-264F-482F-9306-9CD1E6B8AC1B"><gtr:id>6D029004-264F-482F-9306-9CD1E6B8AC1B</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Iredale</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8F27F83F-F830-4172-B687-6D7C1E69BB1F"><gtr:id>8F27F83F-F830-4172-B687-6D7C1E69BB1F</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Tavare</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15041"><gtr:id>3166583F-2C9E-454D-948F-6F2EBD592411</gtr:id><gtr:title>Transforming Translational Research at the University of Bristol</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15041</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>400000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A92DA8DA-FED9-4635-93DB-98C3762F4A74</gtr:id><gtr:title>MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64f42b266fd11aa87e2c88a384ee9d26"><gtr:id>64f42b266fd11aa87e2c88a384ee9d26</gtr:id><gtr:otherNames>Ho GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>5aa7c7e36af2d9.54753624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CEE8791-FA1C-436A-BBF2-DC093D53EC72</gtr:id><gtr:title>Sex differences in the relationship between heavy alcohol use, inhibition and performance monitoring: Disconnect between behavioural and brain functional measures.</gtr:title><gtr:parentPublicationTitle>Psychiatry research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a21e8fce953504093027a338b386bea"><gtr:id>3a21e8fce953504093027a338b386bea</gtr:id><gtr:otherNames>Smith JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-1781</gtr:issn><gtr:outcomeId>5aa7c7e3aa4ad8.20302296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A55C423-7009-488B-86AC-38FE3A849392</gtr:id><gtr:title>av integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/942000b31e6481138d8018ff5f4985d5"><gtr:id>942000b31e6481138d8018ff5f4985d5</gtr:id><gtr:otherNames>Murray IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aa7c7e2250a56.60390245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82320075-F8BD-472A-B650-A5322FFB07CC</gtr:id><gtr:title>11Beta-hydroxysteroid dehydrogenase-1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/323327f946161a4d54706803fcf93469"><gtr:id>323327f946161a4d54706803fcf93469</gtr:id><gtr:otherNames>Zou X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5aa7c7e20525a1.66703524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF047B9F-DECE-43EE-AB08-E7276741F328</gtr:id><gtr:title>Prostaglandin E2 constrains systemic inflammation through an innate lymphoid cell-IL-22 axis.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3577fc614c979ce9faaaf0bb2f68e1e2"><gtr:id>3577fc614c979ce9faaaf0bb2f68e1e2</gtr:id><gtr:otherNames>Duffin R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>58c7e058319ea8.63437575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDEC9A22-7255-464B-9DA9-AB623943E62A</gtr:id><gtr:title>Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.</gtr:title><gtr:parentPublicationTitle>Digestive diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f59ad39a086828f0c6172b2bb84d8eeb"><gtr:id>f59ad39a086828f0c6172b2bb84d8eeb</gtr:id><gtr:otherNames>Iredale JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0257-2753</gtr:issn><gtr:outcomeId>5aa7c7e34ba2a8.87056286</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29CEE1B4-00ED-4352-BFB1-9ED161E77B13</gtr:id><gtr:title>In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe850fd2185775a32e2d3114aa1f4703"><gtr:id>fe850fd2185775a32e2d3114aa1f4703</gtr:id><gtr:otherNames>McBride A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa7c7e2e59606.12363839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B17DE65C-5D69-46DB-A31C-43734291C935</gtr:id><gtr:title>Regression of Liver Fibrosis.</gtr:title><gtr:parentPublicationTitle>Seminars in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c43f9538db5bdad65f025ba2fd94131b"><gtr:id>c43f9538db5bdad65f025ba2fd94131b</gtr:id><gtr:otherNames>Campana L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0272-8087</gtr:issn><gtr:outcomeId>58c7dfa3169784.69739093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F6F3D80-7954-4B28-9151-182DCCFDA5C7</gtr:id><gtr:title>BREXIT and science, where do we go from here.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f59ad39a086828f0c6172b2bb84d8eeb"><gtr:id>f59ad39a086828f0c6172b2bb84d8eeb</gtr:id><gtr:otherNames>Iredale JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>5aa7c7e38cfb85.21872205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1920C2A1-809F-4A93-8541-0D0654433A6E</gtr:id><gtr:title>Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a4d3b6f56f87ded49b6c45e9dea5853"><gtr:id>7a4d3b6f56f87ded49b6c45e9dea5853</gtr:id><gtr:otherNames>Snowdon VK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>58c7df68627ab1.26743942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6045ED2-F812-48C8-ABE8-92AA9754CF34</gtr:id><gtr:title>Low-pathogenicity Mycoplasma spp. alter human monocyte and macrophage function and are highly prevalent among patients with ventilator-acquired pneumonia.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/332649e4ceef3d043cd9c5ac1e91be6f"><gtr:id>332649e4ceef3d043cd9c5ac1e91be6f</gtr:id><gtr:otherNames>Nolan TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58c7d1aad691a8.41622015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A57B54C-CAEF-46E4-B290-1D5326F24900</gtr:id><gtr:title>Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8715cdc6e18b76ebe70866e3231e7367"><gtr:id>8715cdc6e18b76ebe70866e3231e7367</gtr:id><gtr:otherNames>Mole DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>56e003838b8421.65516494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6654C2B9-328C-4491-B9E8-E8DFC3969CEC</gtr:id><gtr:title>Overexpression of human kynurenine-3-monooxygenase protects against 3-hydroxykynurenine-mediated apoptosis through bidirectional nonlinear feedback.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/351bdc8c8becb59d14adc9d737744c16"><gtr:id>351bdc8c8becb59d14adc9d737744c16</gtr:id><gtr:otherNames>Wilson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c7d1aa7f2bc3.53639076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C39E6965-4FF8-4085-9AAA-0CF7986760AE</gtr:id><gtr:title>The STAT3-IL-10-IL-6 Pathway Is a Novel Regulator of Macrophage Efferocytosis and Phenotypic Conversion in Sterile Liver Injury.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c43f9538db5bdad65f025ba2fd94131b"><gtr:id>c43f9538db5bdad65f025ba2fd94131b</gtr:id><gtr:otherNames>Campana L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5aa7c7e1cec772.11958479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06F149B4-964A-47C4-A274-5D18D2D19752</gtr:id><gtr:title>Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c9889ae7226d4262e05a3eb4ee7d9d5"><gtr:id>1c9889ae7226d4262e05a3eb4ee7d9d5</gtr:id><gtr:otherNames>Bertolaccini ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>58c7d1a92b0617.51572065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E952D475-E55C-442E-88B5-7BAC96A95844</gtr:id><gtr:title>Detecting drug-target binding in cells using fluorescence-activated cell sorting coupled with mass spectrometry analysis.</gtr:title><gtr:parentPublicationTitle>Methods and applications in fluorescence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/351bdc8c8becb59d14adc9d737744c16"><gtr:id>351bdc8c8becb59d14adc9d737744c16</gtr:id><gtr:otherNames>Wilson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050-6120</gtr:issn><gtr:outcomeId>5aa7c7e2c56306.73994314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C666D707-A43A-4598-9F41-23663CB241BD</gtr:id><gtr:title>Identifying risk factors for progression to critical care admission and death among individuals with acute pancreatitis: a record linkage analysis of Scottish healthcare databases.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8715cdc6e18b76ebe70866e3231e7367"><gtr:id>8715cdc6e18b76ebe70866e3231e7367</gtr:id><gtr:otherNames>Mole DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58c7d1a82e2347.08122305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CF93AF3-B8B2-423A-AD6E-0F3E099ADD46</gtr:id><gtr:title>Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>Archives of toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/086161dc37d1dafc22f0ce3f56c5730f"><gtr:id>086161dc37d1dafc22f0ce3f56c5730f</gtr:id><gtr:otherNames>Lucendo-Villarin B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0340-5761</gtr:issn><gtr:outcomeId>5aa7c7e320b4e9.60602353</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D79D5F2-910C-4F82-BE77-2615E56DE5AE</gtr:id><gtr:title>Predictive value of cell-surface markers in infections in critically ill patients: protocol for an observational study (ImmuNe FailurE in Critical Therapy (INFECT) Study).</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7f730c06e18455fc8fcea0cdb66c2d"><gtr:id>6d7f730c06e18455fc8fcea0cdb66c2d</gtr:id><gtr:otherNames>Conway Morris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58c7d1a645cad4.53111199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F69641B-E172-43B3-888C-8D7FDBE8DFD2</gtr:id><gtr:title>Increased levels of 3-hydroxykynurenine parallel disease severity in human acute pancreatitis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb3367194780a505914bda6f3e2835c0"><gtr:id>eb3367194780a505914bda6f3e2835c0</gtr:id><gtr:otherNames>Skouras C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c7dfff1d5360.80593165</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15041</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>